Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.75 and traded as high as $4.90. Achieve Life Sciences shares last traded at $4.84, with a volume of 36,588 shares.
Analysts Set New Price Targets
Several brokerages have recently issued reports on ACHV. Oppenheimer reiterated an "outperform" rating and issued a $11.00 target price on shares of Achieve Life Sciences in a research report on Thursday, August 15th. Raymond James began coverage on shares of Achieve Life Sciences in a report on Friday, September 27th. They issued a "strong-buy" rating and a $20.00 price objective for the company.
Read Our Latest Analysis on Achieve Life Sciences
Achieve Life Sciences Price Performance
The company has a debt-to-equity ratio of 0.21, a current ratio of 4.56 and a quick ratio of 4.56. The company's 50-day simple moving average is $4.65 and its 200-day simple moving average is $4.75. The company has a market cap of $162.08 million, a price-to-earnings ratio of -4.25 and a beta of 1.56.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.03). During the same quarter in the prior year, the company posted ($0.43) earnings per share. On average, equities research analysts anticipate that Achieve Life Sciences, Inc. will post -1.03 EPS for the current year.
Institutional Investors Weigh In On Achieve Life Sciences
Several institutional investors have recently made changes to their positions in the company. Propel Bio Management LLC acquired a new position in shares of Achieve Life Sciences during the first quarter worth approximately $11,149,000. Vanguard Group Inc. grew its position in Achieve Life Sciences by 56.6% in the first quarter. Vanguard Group Inc. now owns 948,441 shares of the biopharmaceutical company's stock valued at $4,311,000 after acquiring an additional 342,731 shares during the period. CVI Holdings LLC acquired a new stake in shares of Achieve Life Sciences in the first quarter valued at $2,578,000. Bank of New York Mellon Corp acquired a new stake in shares of Achieve Life Sciences in the second quarter valued at $482,000. Finally, Rhumbline Advisers acquired a new stake in shares of Achieve Life Sciences in the second quarter valued at $197,000. 33.52% of the stock is currently owned by institutional investors and hedge funds.
Achieve Life Sciences Company Profile
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
See Also
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
